Manufacturer record
Cent Cure Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Cent Cure Pvt. Ltd (Himachal Pradesh) were declared Not of Standard Quality between September 2023 and July 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
4 records linked to Cent Cure Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| CLOPIRAS 75 Tablets, Clopidogrel Bisulphate Tablets I.P. | CCT241576Mfg 2024-11 · Exp 2026-10 | Sample does not meets the Specifications wrt. Assay of Clopidogrel as per IP.Assay | State Lab, Drugs Control Laboratory, TelanganaState lab | Jul 2025 |
| Lilion-MR Tablets (Aceclofenac, Paracetamol & Chlorzoxazone Tablets) | CCT24984BMfg 2024-07 · Exp 2026-06 | Assay for Aceclofenac and ChlorzoxazoneAssay | State Lab KarnatakaState lab | Jun 2025 |
| Pantakos-40 (Pantoprazole Gastro-resistant Tablets IP ) | CCT231092 BMfg 2023-09 · Exp 2025-08 | THE SAMPLE DOES NOT COMPLY WITH IP REQUIREMENTS FOR DISSOLUTION IN BUFFER STAGE.Dissolution | State Lab MaharashtraState lab | Jun 2024 |
| RABEPRAZOLE SODIUM GASTRO-RESISTANT TABLETS IP (RABIRIV-20 TABLETS) | CCT22065AMfg 2022-08 · Exp 2024-07 | Assay of Rabeprazole SodiumAssay | RDTL GuwahatiState lab | Sep 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.